{"entity":{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","aka":["Luye Pharma Group Ltd.","Luye Pharma","绿叶制药"],"tldr":"Luye Pharma is a Chinese pharmaceutical group, listed in Hong Kong, whose oncology business rests on paclitaxel liposome (Lipusu) and other reformulated cancer medicines.","summary":"Luye Pharma Group, based in Yantai in Shandong and listed on the Hong Kong stock exchange, develops and sells medicines in oncology, the central nervous system and cardiovascular disease, with a focus on new formulations and long-acting delivery. Its best-known cancer product is Lipusu, a liposomal formulation of paclitaxel widely used in China, and it runs phase 3 trials of reformulated chemotherapy and targeted agents. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.luye.cn"},{"label":"ClinicalTrials.gov: trials led by Luye Pharma","url":"https://clinicaltrials.gov/search?lead=Luye%20Pharma"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Luye_Pharma_Group"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Yantai","country":"CN","companyType":"pharma","website":"https://www.luye.cn","stage":"public","investors":[],"funding":[]},"route":"/companies/luye-pharma/","neighbours":{"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"drug":[{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}]}}